“Problematic” settlements of pharmaceutical patents in the EU are decreasing, according to a European Commission report.
These include settlements in which a company holding a medicine patent pays another to delay entry of a generic drug on the market.
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.